OraSure Technologies, Inc. Announces $40 Million Stock Repurchase Program

OraSure Technologies announced a $40 million stock repurchase plan over 24 months, funded by cash on hand.

Quiver AI Summary

OraSure Technologies, Inc. has announced a plan to repurchase up to $40 million of its common stock over the next two years, utilizing cash on hand for the purchases. The Board of Directors will grant management the discretion to determine the amount and timing of these repurchases, which will comply with all relevant securities laws. Additionally, the repurchase program can be altered or stopped at the company's discretion without prior notice. OraSure is dedicated to improving healthcare access and quality through innovative diagnostic tests and sample management solutions, serving a wide range of customers, including healthcare providers, research institutions, and consumers.

Potential Positives

• OraSure Technologies, Inc. has authorized a significant stock repurchase program of up to $40 million, indicating strong financial health and commitment to returning value to shareholders.
• The repurchase will be funded from cash on hand, showcasing the company's favorable liquidity position.
• This authorized buyback could potentially enhance earnings per share by reducing the overall number of shares outstanding, which may attract more investors.

Potential Negatives

• The repurchase program may be modified, suspended, or discontinued at any time at the Company’s discretion without prior notice, which may create uncertainty for investors about the reliability and commitment to the program.
• Forward-looking statements included in the release indicate that actual performance may significantly differ, highlighting potential volatility and risk factors that could concern stakeholders.

FAQ

What is OraSure Technologies' stock repurchase program?

OraSure Technologies has authorized a stock repurchase program for up to $40 million over the next twenty-four months.

What will fund the stock repurchase program?

The stock repurchase program will be funded from the Company's cash on hand.

Who determines the timing of stock repurchases?

The timing and amount of stock repurchases will be determined at Management's discretion.

Can the stock repurchase program be modified?

Yes, the repurchase program may be modified, suspended, or discontinued at any time without prior notice.

Where can I find more information about OraSure Technologies?

More information about OraSure Technologies can be found on their website at www.orasure.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$OSUR Insider Trading Activity

$OSUR insiders have traded $OSUR stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $OSUR stock by insiders over the last 6 months:

• MANNER CARRIE EGLINTON (President & CEO) has made 2 purchases buying 107,295 shares for an estimated $347,404 and 0 sales.
• KENNETH J MCGRATH (Chief Financial Officer) purchased 64,000 shares for an estimated $201,683
• JOHN P. KENNY purchased 47,659 shares for an estimated $151,217
• NANCY J GAGLIANO purchased 12,750 shares for an estimated $39,270
• LELIO MARMORA purchased 7,000 shares for an estimated $21,420

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$OSUR Hedge Fund Activity

We have seen 80 institutional investors add shares of $OSUR stock to their portfolio, and 131 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• UBS GROUP AG added 1,529,001 shares (+4775.6%) to their portfolio in Q4 2024, for an estimated $5,519,693
• CANNELL CAPITAL LLC removed 1,005,794 shares (-40.7%) from their portfolio in Q4 2024, for an estimated $3,630,916
• D. E. SHAW & CO., INC. added 976,475 shares (+180.5%) to their portfolio in Q4 2024, for an estimated $3,525,074
• BNP PARIBAS FINANCIAL MARKETS removed 769,989 shares (-90.0%) from their portfolio in Q4 2024, for an estimated $2,779,660
• BLACKROCK, INC. removed 652,905 shares (-8.6%) from their portfolio in Q4 2024, for an estimated $2,356,987
• RENAISSANCE TECHNOLOGIES LLC added 521,400 shares (+23.1%) to their portfolio in Q4 2024, for an estimated $1,882,254
• ARCHON CAPITAL MANAGEMENT LLC added 490,034 shares (+145.1%) to their portfolio in Q4 2024, for an estimated $1,769,022

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand.

The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. The amount and timing of share repurchases will be determined by Management at its discretion. The repurchase program may be modified, suspended, or discontinued at any time at the Company’s discretion without prior notice.

About OraSure Technologies, Inc.



OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure, please visit

www.orasure.com

Forward Looking Statements



This Press Release contains certain “forward-looking statements” within the meaning of the Federal securities laws, including with respect to the Stock Repurchase Plan and the factors that will impact the amount and timing of purchases, if any, thereunder. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to, changes in price and volume and the volatility of the Common Stock and the other risk factors disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s subsequent filings with the SEC. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.